K-V Pharmaceutical has created a new marketing subsidiary for generic drugs, the company said. K-V announced the establishment of Nesher Pharmaceuticals, appointing as its president Mark Hartman, who has had several positions in generic drug companies.
“Mark brings recognized depth and breadth of generic industry experience and leadership to K-V,” K-V interim president and CEO Greg Divis said. “We are excited to have Mark join our organization and look forward to him leading the introduction of Nesher Pharmaceuticals Inc., K-V’s new generic subsidiary.”
The Food and Drug Administration granted approval for Teva’s abbreviated new drug application to market a generic version of a drug designed to treat peptic ulcers. The generic drug maker said that its drug, lansoprazole, is a generic version of Takeda’s Prevacid SoluTab. Annual sales of the branded product were approximately $453 million in the United States, according to IMS sales data. Sandoz, the generics division of Swiss drug maker Novartis, also announced the launch of its own version of Prevacid SoluTab.
The Food and Drug Administration has approved two generic drugs by Mylan for treating hypertension, Mylan said. The company announced the approval of losartan potassium and hydrochlorothiazide tablets in the 50/12.5-mg and 100/25-mg strengths, and losartan potassium tablets in the 25-mg, 50-mg and 100-mg strengths, generic versions of Merck’s Hyzaar and Cozaar, respectively. Mylan began marketing its version of Hyzaar in the 100/12.5-mg strength in April. Various versions of Hyzaar in the two strengths had sales of around $570 million during the 12-month period ended in June, while versions of Cozaar had sales of $940 million, according to IMS Health.
The Food and Drug Administration has approved a drug for treating insomnia made by Actavis, the generic drug maker said. Actavis announced the approval of zolpidem tartrate extended-release tablets in the 6.25-mg strength. The company has begun shipping the drug, a generic version of Sanofi-Aventis’ Ambien CR, which had sales of around $129 million during the 12-month period ended in June, according to IMS Health.
The Food and Drug Administration has approved a Watson Pharmaceuticals generic drug for treating high blood pressure, Watson said. The company announced the FDA approval of amlodipine besylate and benazepril capsules in the 5/20-mg, 10/20-mg, 2.5/10-mg and 5/10-mg strengths. The drug is a generic version of Novartis’ Lotrel. Branded and generic versions of the drug had sales of around $1.05 billion during the 12-month period ended in June, according to IMS Health.
Drug maker Hospira has launched a generic treatment for bacterial infections, Hospira said. The company, which specializes in generic injectables, announced the launch of piperacillin and tazobactam for injection. The drug is a generic version of Pfizer’s Zosyn.
Various versions of the drug had sales of $797 million during the 12-month period ended in August, according to IMS Health. Sandoz, the generics division of Novartis, also launched its own version of the drug.